Literature DB >> 24313556

Safety of paediatric percutaneous native kidney biopsy and factors predicting bleeding complications.

Pornpimol Rianthavorn1, Stephen J Kerr, Kanhatai Chiengthong.   

Abstract

AIM: Data on safety of paediatric percutaneous native kidney biopsy (PNKB) using automated biopsy devices and real-time ultrasonography are lacking. The objective of this study was to evaluate the safety and to identify factors predicting bleeding complications associated with this PNKB protocol.
METHODS: A total of 227 patients aged <18 years who underwent the first PNKB were analyzed. The primary outcome was bleeding complications divided into minor and major bleeding complications. Minor bleeding complications included perirenal haematoma and macroscopic haematuria. Major bleeding complications included requirement of blood transfusion, a higher level of care or vasopressors to maintain haemodynamic stability, requirement of angiographic or surgical intervention, or death.
RESULTS: Perirenal haematoma occurred in 58 patients (25%) and macroscopic haematuria occurred in 46 patients (20%). Two factors were independently associated with perirenal haematoma in a multivariate model. These were male gender and weight for height Z-score <-0.5. Three patients (1.3%), all with perirenal haematoma had major bleeding complications (two required blood transfusion and one underwent surgery to repair an injured renal artery).
CONCLUSIONS: The favourable safety information from our study is useful when counselling the parents and patients undergoing similar protocols. PNKB can be safely performed when precautions are taken to prevent bleeding. Selection of biopsy instruments should be tailored according to patient size.
© 2013 Asian Pacific Society of Nephrology.

Entities:  

Keywords:  bleeding; complication; native kidney biopsy; paediatric; perirenal haematoma

Mesh:

Substances:

Year:  2014        PMID: 24313556     DOI: 10.1111/nep.12184

Source DB:  PubMed          Journal:  Nephrology (Carlton)        ISSN: 1320-5358            Impact factor:   2.506


  7 in total

Review 1.  Major bleeding after percutaneous image-guided biopsies: frequency, predictors, and periprocedural management.

Authors:  Sean A Kennedy; Lazar Milovanovic; Mehran Midia
Journal:  Semin Intervent Radiol       Date:  2015-03       Impact factor: 1.513

2.  Urinary CD80 levels as a diagnostic biomarker of minimal change disease.

Authors:  Chen Ling; Xiaorong Liu; Ying Shen; Zhi Chen; Jianfeng Fan; Yeping Jiang; Qun Meng
Journal:  Pediatr Nephrol       Date:  2014-08-21       Impact factor: 3.714

3.  Risk factors for complications of percutaneous ultrasound-guided renal biopsy in children.

Authors:  Jhao-Jhuang Ding; Shih-Hua Lin; Jing-Long Huang; Tai-Wei Wu; Shao-Hsuan Hsia; Jainn-Jim Lin; Yu-Ching Chou; Min-Hua Tseng
Journal:  Pediatr Nephrol       Date:  2019-11-14       Impact factor: 3.714

4.  Bleeding Complications after Pediatric Kidney Biopsy: A Systematic Review and Meta-Analysis.

Authors:  Charles D Varnell; Hillarey K Stone; Jeffrey A Welge
Journal:  Clin J Am Soc Nephrol       Date:  2018-12-06       Impact factor: 8.237

5.  Absorption fever characteristics due to percutaneous renal biopsy-related hematoma.

Authors:  Tingyang Hu; Qingquan Liu; Qin Xu; Hui Liu; Yan Feng; Wenhui Qiu; Fei Huang; Yongman Lv
Journal:  Medicine (Baltimore)       Date:  2016-09       Impact factor: 1.889

6.  Kidney biopsy guidebook 2020 in Japan.

Authors:  Yoshifumi Ubara; Takehiko Kawaguchi; Tasuku Nagasawa; Kenichiro Miura; Takayuki Katsuno; Takashi Morikawa; Eiji Ishikawa; Masao Ogura; Hideki Matsumura; Ryota Kurayama; Shinsuke Matsumoto; Yuhji Marui; Shigeo Hara; Shoichi Maruyama; Ichiei Narita; Hirokazu Okada; Kazuhiko Tsuruya
Journal:  Clin Exp Nephrol       Date:  2021-04       Impact factor: 2.801

7.  Clinical application of a phenotype-based NGS panel for differential diagnosis of inherited kidney disease and beyond.

Authors:  Jiyoung Oh; Jae Il Shin; Keumwha Lee; CheolHo Lee; Younhee Ko; Jin-Sung Lee
Journal:  Clin Genet       Date:  2020-12-07       Impact factor: 4.438

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.